RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy
Start Date
8/10/2017
Completion Date
4/1/2026
Summary
Chemotherapy-induced nausea and vomiting (CINV) are among the most bothersome symptoms during cancer treatment according to children and their parents. Most children receiving highly emetogenic chemotherapy (HEC), including those receiving hematopoietic stem cell transplant (HSCT) conditioning, experience CIV despite receiving antiemetic prophylaxis. Olanzapine improves CINV control in adult cancer patients, has a track record of safe use in children with psychiatric illness, does not interact with chemotherapy and is inexpensive. We hypothesize that the addition of olanzapine to standard antiemetics will improve chemotherapy-induced vomiting (CIV) control in children receiving highly emetogenic chemotherapy
Eligibility Criteria
Age Range: No minimum to 18 years
Interventions
Olanzapine
Placebo Oral Tablet
Conditions
Locations
University of California
San Francisco, California 94158
United States
The Children's Mercy Hospital
Kansas City, Missouri 64108
United States
Columbia University/Morgan Stanley Children's Hospital
New York, New York 10032
United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina 27599-7220
United States
Nationwide Children's Hospital
Columbus, Ohio 43205
United States
Medical University of South Carolina
Charleston, South Carolina 29425
United States
Cancer Care Manitoba
Winnipeg, Manitoba R3E 0V9
Canada
Hospital for Sick Children
Toronto, Ontario M5G 1X8
Canada
Centre Hospitalier Universitaire Sainte-Justine,
Montreal, Quebec H3T 1C5
Canada
All India Institute of Medical Sciences
New Delhi, National Capital Territory of Delhi 110029
India